Wide range of prevalence reported, with some suggesting that LVNC is actually a physiological adaptation that can occur in healthy individuals. One study found that prevalence among three healthy control cohorts was 1.05% (95% CI 0.00–7.88; I 2 = 87.95%) and in two non-cardiac patient cohorts was 2.21% (95% CI 0.24–5.46), but found much higher prevalence in cohorts of athletes or pregnant women. They also found a significant difference between prevalence estimates when the method of dx was echo vs. cardiac MRI. (PMID: 31143950)
Another study found that the prevalence in newborns was 0.076% (95% CI, 0.047–0.123) (PMID: 35727876).
MYH7 truncating and non-truncating variants are significantly enriched in LVNC cohorts (see PMID 33500567).
PMID: 29447731: study of 327 unrelated patients with non-compaction cardiomyopathy. 45 cardiomyopathy genes were tested. Of the 104 likely genetic cases, MYH7 was the most frequently mutated gene in 19% (n = 10) of children and 11% (n = 29) of adults. 2 children had a pathogenic variant in MYH7 and Ebstein anomaly.
Reported variants (all are LP/P by authors), see supplemental tables 1a and 2a:
c.495G>A, p.(Met165Ile) - 1 affected child w/fhx NCCM. P/LP in ClinVar. Absent from GnomAD v4. REVEL = 0.864. (0.1pts)
c.689T>C, p.(Phe230Ser) - 1 affected child w/fhx NCCM, pt also had Ebstein anomaly. Absent from GnomAD v4. VUS/LP in ClinVar. REVEL = 0.956. (0.1pts)
c.728G>A, p.(Arg243His)- 1 affected child w/fhx NCCM. VUS/LP/P in ClinVar. 2 individuals in GnomAD v4. REVEL: 0.969. (0.1pts)
c.732+1G>A, p.(?) - 1 affected child w/fhx NCCM. P/LP in ClinVar. 1 individual in GnomAD v4. Nearest exon is in-frame, NMD-. (0.5pts)
c.798T>A, p.(Tyr266*) - 1 affected child w/fhx NCCM. Not in ClinVar. Absent from GnomAD (1 point)
c.1106G>A, p.(Arg369Gln) - 1 affected child, no fhx reported. LP by expert panel in ClinVar. They cite (Dellefave 2009 PMID: 20031619; Hoedemaekers 2010 PMID: 20530761; Tian 2015 PMID: 24691700; Li 2018 PMID: 30371277; Centenary Institute Sydney pers. comm.; GeneDx pers. comm.; Invitae pers. comm.; LMM pers. comm.; OMGL pers comm). (0.1pts, could upgrade)
c.2710C>T, p.(Arg904Cys) - 1 affected adult w/fhx NCCM and DCM
c.3100-2A>C, p.(?) - 1 affected adult, no fhx reported.
c.4075C>T, p.(Arg1359Cys) - 1 affected adult, no fhx reported.
c.4125T>A, p.(Tyr1375*) - 1 affected adult w/fhx ARVC. VUS in ClinVar. 5 individuals in GnomAD v4. (1pt)
c.5754C>G, p.(Asn1918Lys) - 6 affected adults, at least one pt had Ebstein anomaly. P in ClinVar. Absent from GnomAD. REVEL: 0.693. (0.6pts)
c.5773C>G, p.(Arg1925Gly) - 2 affected adults
PMID: 35527761:
c. 3830G>C p.Arg1277Pro - 6mo proband and mother with LVNC. Sequenced 151 genes associated with cardiomyopathy and both mother and child carried this variant, father did not. Other potentially affected family members were not tested. VUS in ClinVar. Variant is absent from GnomAD . REVEL: 0.656. Add 0.1 pts for segregation (0.2pts)
PMID: 25415959:
c.1316T>G M439R - 49yo M proband with LVNC and bicuspid aortic valve (BAV). Proband’s son, daughter, and grandson all had the same diagnoses. The variant segregated in the son and grandson, was not tested in the daughter (see fig 1). 27 gene panel. LP by one submitter in ClinVar. Absent from GnomAD. REVEL=0.965. Add 0.2 pts for segregations (0.3pts)
PMID: 18506004: cohort of 63 patients with LVNC. 6 genes evaluated. Same cohort described in PMID: 21551322.
c.732+1G>A (described as c.818+1G>A). Family LVNC-101. 4 affected segregations. Variant is P/LP in ClinVar. Also described in PMID: 29447731. Nearest exon is in-frame. (0.5pts)
c.728G>A (described as c.814G>A), p.Arg243His. Family LVNC-107. 2 affected segregations. Variant is VUS by expert panel in ClinVar. Also described in PMID: 29447731. (0.1pts)
c.818+3G>C
c.801_803delGAC p.Asp239del
c.840T>C p.Phe252Leu
c.4161C>T p.Arg1359Cys
c.5296G>A (described as c.5382G>A) p.Ala1766Thr, de novo. Individual MT. VUS/P in ClinVar. Absent from GnomAD v4. REVEL: 0.68. (0.6pts)
PMID: 36292635:
c.895+1G>A: 22yo proband and 53 yo father with isolated LVNC. Proband had mitral valve prolapse and heart failure. WGS was conducted on the proband, mother, father, and brother and MYH7 c.895+1G>A was identified in proband and father. Exon 10 is in-frame. Authors hypothesize exon skipping. (0.5pts)
Clinical ValidityPoints Total
7 points reached, did not curate further.
Clinical ValidityClassification
Definitive (12pts)
Strong (12pts)
Moderate (7-11pts)
Limited (0.1-6pts)
No genetic evidence
Refuted
Disputed
At least moderate.
Source:
MolecularMechanism
Loss of function
Gain of function
Dominant negative
Unknown
Other
Loss of function / Gain of function / Dominant Negative
“MYH7 truncating variants (MYH7tv), generally considered nonpathogenic for cardiomyopathies, were 20-fold enriched in LVNC cases over controls. MYH7tv heterozygotes identified in the UK Biobank and healthy volunteer cohorts also displayed significantly greater noncompaction compared with matched controls.” PMID: 33500567
Penetrance
Complete (100%)
High (≥80%)
Moderate (<80% and >20%)
Low (≤20%)
(list source/PMID)
Source:
Age of Onset
Congenital
Pediatric
Adolescent
Adulthood
Late adulthood
(list source/PMID)
Severity
Clinical Features
LVNC with or without CHDs, arrhythmias. Subtypes include Isolated LVNC, Dilated LVNC, Hypertrophic LVNC.